Navigation Links
Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
Date:6/1/2009

mine bitartrate are fully-compliant due to the drug's strict every-six hour dosing schedule and dose-limiting side effects, including gastrointestinal ("GI") problems such as stomach aches, nausea and vomiting.

Patrice Rioux, M.D., Ph.D., Raptor's Chief Medical Officer stated, "We are pleased that enrollment is now underway in our Phase 2b clinical trial in cystinosis. This is an underserved patient population and there is a compelling need for an improved treatment option. Many patients are unable to take adequate levels of the drug to halt the progression of their disease, which gradually destroys the organs in the body. We believe DR Cysteamine could have positive effects on the long-term health of cystinosis patients as well as the quality of life for patients, their families and caregivers."

Bruce Barshop, M.D., Ph.D., Professor of Clinical Pediatrics at UCSD and principal investigator for the cystinosis clinical trial, commented, "The initiation of this cystinosis trial offers us an opportunity to evaluate the potential for an improved treatment invented here at UCSD and further developed by Raptor. We're pleased to collaborate with Raptor in this effort to advance the standard of care in cystinosis."

About DR Cysteamine

DR Cysteamine is an enteric-coated micro-bead formulation of cysteamine bitartrate. Raptor obtained an exclusive, worldwide license to DR Cysteamine, as well as orphan drug designation from the FDA for DR Cysteamine for the treatment of nephropathic cystinosis, through its December 2007 acquisition of Encode Pharmaceuticals. In March 2008, Raptor acquired an exclusive worldwide license to intellectual property from the University of California, San Diego for use of cysteamine and DR Cysteamine for the treatment of non-alcoholic steatohepatitis ("NASH"), a progressive liver disease believed to affect 2-5% of the U.S. population. In October, 2008 Raptor ann
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
2. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
3. Raptor Pharmaceuticals Closes $10 Million Private Placement
4. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
5. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
6. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
7. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
8. Raptor Pharmaceuticals Acquires Orphan Clinical Program
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
11. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015 Bionomics Limited (ASX:BNO, ADR:BMICY) ... trial of BNC105 in patients with metastatic renal cancer ... Orlando, Florida . The data will be presented ... of Hope Comprehensive Cancer Center in California ... The new data identifies Ferritin and IL-8 as two ...
(Date:2/27/2015)... February 27, 2015 Cytokinetics, Incorporated (Nasdaq: ... February 28 with patients and health care advocates in ... Rare Disease Day®. Rare Disease Day is dedicated ... attention to the special challenges faced by patients with ... “Cytokinetics is proud to stand alongside patients and caregivers ...
(Date:2/26/2015)... 26, 2015 S&P Capital IQ (MHFI) announced ... coverage on MabVax Therapeutics Holdings Inc . ... stage biotechnology company focused on the development of vaccine ... the treatment of cancer. MabVax has discovered a pipeline ... immune responses generated by patients who have been immunized ...
(Date:2/26/2015)... , Feb. 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... life sciences company that develops and commercializes proprietary technologies ... financial and operational results for the fiscal first quarter ... release are in Canadian dollars (CAD), unless otherwise stated. ... to win new business from our existing customers and ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... BEIJING, Sept. 8 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.,(NYSE Amex: ... China, today announced,that the first lot of PANFLU.1, its H1N1 ... for the Control of Pharmaceutical and,Biological Products and obtained the ... vaccines are ready for delivery. , ...
... SANTA CLARA, Calif., Sept. 8 Cell Biosciences, ... announced that they have entered into a definitive agreement providing ... $1.50 per share or approximately $17.9 million in cash. This ... include a global infrastructure and a broad protein analysis product ...
... LAIYANG, China, Sept. 8 /PRNewswire-Asia-FirstCall/ -- Jiangbo,Pharmaceuticals, Inc. (OTC ... with its principal operations in the People,s,Republic of China, ... The Company expects to meet or exceed its ... income of $40 to $43 million for the,fiscal year ...
Cached Biology Technology:Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine 2Cell Biosciences Signs Agreement to Acquire Alpha Innotech 2Cell Biosciences Signs Agreement to Acquire Alpha Innotech 3Cell Biosciences Signs Agreement to Acquire Alpha Innotech 4Cell Biosciences Signs Agreement to Acquire Alpha Innotech 5Jiangbo Pharmaceuticals Reaffirms Guidance for Fiscal 2009 2
(Date:2/5/2015)... , Jan. 28, 2015 Research and ... the addition of the "Global Biometrics Market ... Regions and Countries " report to their offering. ... Asia-Pacific is anticipated to ... 2015, owing to increasing government spending towards IT ...
(Date:2/5/2015)... Feb. 3, 2015 Despite a lack ... industries such as consumer electronics, automotive, storage and ... mount technology (SMT) screen printers. Innovations in electronics ... will push the adoption curve up. Meanwhile, sale ... as glue dispensers are indispensable in the production ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... molecule known to be involved in progressive heart failure ... damage after a heart attack, according to researchers at ... conclusion, the research team used gene therapy to inhibit ... kinase 2 (GRK2), and found heart muscles cells in ...
... a new study this week, Rice University scientists bring the ... the processes of natural selection and evolution influence the way ... online from Physical Review Letters . It builds upon ... in the past decade -- the revelation that bacteria and ...
... The European Society for Medical Oncology (ESMO) honors three eminent ... research. The awards will be presented to Hilary Calvert, Alberto ... take place from 8-12 October in Milan, Italy. Dr ... for his key role in the development of international guidelines ...
Cached Biology News:Molecule involved in heart failure now implicated in heart attack damage 2Rice study examines how bacteria acquire immunity 2Rice study examines how bacteria acquire immunity 3Top cancer specialists receive ESMO awards 2Top cancer specialists receive ESMO awards 3Top cancer specialists receive ESMO awards 4
... rat tissue extracts (liver, kidney, spleen, and heart) ... extract. It was also tested with microsomal fractions ... A simple and reliable method for measuring NDPase ... of the inorganic phosphate released from NDP by ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selecitivty and potential CNS-Side Effect liabilities of compo...
... tested through 63 ligand ... spanning a broad therapeutic ... includes many non human ... non-selective assays. Used ...
... PolarScreen Progesterone Receptor (PR) Competitor Assay ... screening novel progesterone receptor binding compounds ... assay utilizes a fusion of glutathione ... of human progesterone receptor [PR-LBD(GST)] and ...
Biology Products: